RxNews®

September 5, 2025 - The FDA approved Takeda’s Vonvendi (von Willebrand factor [recombinant]), in adult and pediatric patients with von Willebrand disease (VWD) for on-demand treatment and control of bleeding episodes and perioperative management of bleeding.

August 29, 2025 - The FDA approved Amgen’s Otezla XR (apremilast) extended-release tablets for the treatment of adult and pediatric patients (6 years of age and older, weighing at least 50 kg) with active psoriatic arthritis; adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy; pediatric patients (6 years of age and older, weighing at least 50 kg) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy; and adult patients with oral ulcers associated with Behçet’s disease.